Method of administration and treatment
Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.
1. A method of treating a gout, comprising administering a transdermal formulation comprising a buffering agent, wherein the transdermal formulation comprising the buffering agent is administered to a patient having abnormal levels of uric acid crystals in one or more joints, tendons or surrounding tissue, and wherein the buffering agent reduces the levels of uric acid crystals in the one or more joints, tendons or surrounding tissue of said patient, resulting in a reduction in the symptoms of the a gout, wherein the buffering agent consists of sodium bicarbonate.
2. The method of claim 1 , wherein the transdermal formulation is administered to a patient topically.
3. The method of claim 1 , wherein the transdermal formulation raises the pH in the vicinity of where the patient is suffering from gout.
4. The method of claim 1 , wherein the transdermal formulation reduces the level of uric acid at the site where the patient is suffering from gout.
5. The method of claim 1 , wherein the transdermal formulation reduces the effects of diseases resultant from gout.
6. The method of claim 5 , wherein the disease is osteoarthritis, rheumatoid arthritis or psoriatic arthritis.
7. The method of claim 1 , wherein the sodium bicarbonate is at a concentration from about 30% to 35% w/w of the transdermal formulation.
8. The method of claim 1 , wherein the sodium bicarbonate is at a concentration of 33% w/w of the transdermal formulation.
9. The method of claim 1 , wherein the gout is one or more of a recurrent gout attack, gouty arthritis, hyperuricemia, gout related cardiovascular disorders (e.g. hypertension, cardiovascular disease, coronary heart disease), Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, inflammatory joint disease, arthritis, osteoarthritis, rheumatoid arthritis and psoriatic arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis or sarcoidosis.
10. The method of claim 1 , wherein the buffering agent penetrates the skin of the patient.
11. The method of claim 1 , wherein the transdermal formulation comprises the buffering agent in an amount between about 10%-45% w/w; a penetrant portion in an amount between about 5%-55% w/w; a detergent portion in an amount between about 1% to 15% w/w; and water in an amount between about 15% to 65% w/w.
12. The method of claim 1 , wherein the transdermal formulation further comprises menthol.
13. The method of claim 12 , wherein the menthol is at a concentration from about 0.1% to 5.0% w/w of the transdermal formulation.
14. The method of claim 13 , wherein the menthol is at a concentration of about 0.5% w/w of the transdermal formulation.
15. The method of claim 14 , wherein the sodium bicarbonate is at a concentration of about 33% w/w of the transdermal formulation.
16. The method of claim 15 , wherein the transdermal formulation is formulated as a cream, lotion or ointment.
17. A method of treating a gout, comprising administering a transdermal formulation comprising a buffering agent, wherein the transdermal formulation comprising the buffering agent is administered to a patient having abnormal levels of uric acid crystals in one or more joints, tendons or surrounding tissue, and wherein the buffering agent reduces the levels of uric acid crystals in the one or more joints, tendons or surrounding tissue of said patient, resulting in a reduction in the symptoms of the gout, wherein the buffering agent consists of sodium carbonate.
18. The method of claim 17 , wherein the transdermal formulation further comprises menthol at a concentration of about 0.5% w/w of the transdermal formulation.
19. The method of claim 18 , wherein the sodium carbonate is at a concentration of about 33% w/w of the transdermal formulation.
20. The method of claim 19 , wherein the transdermal formulation is formulated as a cream, lotion or ointment.